Novartis India Share Price
Small Cap | Pharmaceuticals and health care | BSE: 500672
₹802.10 
3.20 (0.40 %)
Last Updated: 04 Apr 2025 04:01 PM
BEARISH
Overview
Open (₹) 794.00
High (₹) 824.85
Low (₹) 791.10
Prev. Close (₹) 798.90
Volume 8,496
VWAP (₹) 805.54
ROCE (%) 16.19
Industry P/E 44.73
TTM P/E 22.96
P/B Ratio 2.66
Market Cap (₹) Cr.1,980.45
Dividend Yield (%)3.12
EPS (₹) 34.50
ROE11.43%
Sales Growth (%) -11.53
Profit Growth (%)-17.58
Day Range
824.85824.85
52 Week Range
744.951,248.00
Historical Returns
Returns (6M)
-20.85 %
Returns (1Y)
-26.48 %
Returns (3Y)
23.98 %
Returns (5Y)
53.15 %
Returns (6M)
-20.85 %
Returns (1Y)
-26.48 %
Returns (3Y)
23.98 %
Returns (5Y)
53.15 %
SWOT Analysis
- Growth in Net Profit Margin (QoQ)
- Growth in Annual Net Profit with increasing Profit Margin (YoY)
Technicals
Technical Rating
BEARISHRSI 46.07
MFI 37.92
ATR 27.90
Commodity Channel Index -112.26
ROC125 -27.96
ROC21 -6.20
Williams %R -84.81
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 819.60 | 836.75 | 848.55 | 807.80 | 790.65 | 778.85 | 761.70 |
| Week Ago | 842.34 | 848.67 | 853.34 | 837.67 | 831.34 | 826.67 | 820.34 |
| Month Ago | 918.99 | 945.92 | 964.84 | 900.07 | 873.14 | 854.22 | 827.29 |
EMA & SMA
802.10
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
20
5 Day 829.58
9 Day 816.25
10 Day 815.90
12 Day 824.49
14 Day 828.15
20 Day 836.31
26 Day 849.88
50 Day 882.40
100 Day 966.33
200 Day 1035.03
Deals & Announcements
Bulk and Block Deals
Insider Trading
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 10 May, 2024 | Rs.25.0000 per share(500%)Final Dividend | 23 Jul, 2024 | 01 Jan, 1970 |
| 11 May, 2023 | Rs.37.5000 per share(750%)Special Dividend | 20 Jul, 2023 | 01 Jan, 1970 |
| 10 May, 2023 | Rs.10.0000 per share(200%)Final Dividend | 20 Jul, 2023 | 01 Jan, 1970 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 27 Mar, 2025 | BSE India | Filing of Intimation under Regulation 30 for the receipt of draft tax assessment order by the Company |
| 27 Mar, 2025 | BSE India | Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2025 ,inter alia, to consider and approve The meeting of the Board of Directors of the Company is scheduled to be held on Friday, May 09, 2025 to inter alia consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2025 and to recommend dividend on Equity Shares of the Company, if any. |
| 04 Mar, 2025 | BSE India | Integrated filing (Financial) for the Quarter and nine months ended December 31 2024. |
| 20 Feb, 2025 | BSE India | This is to inform that the Company has received order from Assistant Commissioner of CGST and Central Excise and disclosure is given pursuant to Regulation 30 read with Clause 20 Para A of Schedule III |
| 28 Jan, 2025 | BSE India | We hereby inform that the Board of Directors ('Board') of the Company at its Meeting held today i.e. January 28, 2025 inter-alia have considered and approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024 as recommended by the Audit Committee of the Company. |
| 27 Dec, 2024 | BSE India | NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 ,inter alia, to consider and approve The intimation is filed to inform that the Board Meeting of the Company shall be held on Tuesday, January 28, 2025, for approval of Quarterly Financial Results for the Quarter ended as on December 31, 2024. |
| 25 Oct, 2024 | BSE India | Filing of the outcome of Board Meeting and Unaudited Financial Results for the quarter and half year ended September 30, 2024 |
| 11 Oct, 2024 | BSE India | Filing of Certificate dated 03.10.2024 under regulation 74(5) received from the Companys'' RTA for the quarter ended Sept 30, 2024 |
| 27 Sept, 2024 | BSE India | NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 ,inter alia, to consider and approve the Unaudited Financial Results for the quarter ended September 30, 2024 |
| 26 Sept, 2024 | BSE India | Filing of clarification on the email received from BSE dated September 26, 2024, on the rumor in relation to acquisition of Novartis India Limited from its Swiss Parent Company by Alkem Labs. |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Audited Results & Final Dividend | -- | 28 Mar, 2025 | 09 May, 2025 |
| Quarterly Results | -- | 28 Dec, 2024 | 28 Jan, 2025 |
| Quarterly Results | -- | 01 Oct, 2024 | 25 Oct, 2024 |
| Audited Results & Final Dividend | -- | 01 Apr, 2024 | 10 May, 2024 |
| Quarterly Results | -- | 28 Dec, 2023 | 25 Jan, 2024 |
| Quarterly Results | -- | 05 Oct, 2023 | 27 Oct, 2023 |
| Quarterly Results | -- | 03 Jul, 2023 | 26 Jul, 2023 |
| Audited Results, Final & Special Dividend | -- | 11 May, 2023 | 10 May, 2023 |
| Quarterly Results | -- | 28 Dec, 2022 | 08 Feb, 2023 |
| Quarterly Results | -- | 04 Oct, 2022 | 09 Nov, 2022 |
Share Holding Pattern
| Owner Name | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
|---|---|---|---|---|---|
| Promoter Group | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% |
| Foreign Institutions + | 0.19% | 0.19% | 0.17% | 0.09% | 0.05% |
| Domestic Institutions + | 0.53% | 0.53% | 0.78% | 0.77% | 0.78% |
| Government | 0% | 0% | 0% | 0% | 0% |
| Public | 28.6% | 28.6% | 28.37% | 28.46% | 28.49% |
| Others | 0% | 0% | 0% | 0% | 0% |
About Novartis India
Novartis India is a Public Limited Listed company incorporated on 13/12/1947 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24200MH1947PLC006104 and registration number is 006104. Currently Company is involved in the business activities of Wholesale of pharmaceutical and medical goods. Company’s Total Operating Revenue is Rs. 335.07 Cr. and Equity Capital is Rs. 12.34 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Novartis AG
Founded
1947
Managing Director
-- --
NSE Symbol
--
Novartis India Management
| Name | Designation |
|---|---|
| Mr. Christopher Snook | Chairperson |
| Mrs. Shilpa Joshi | WholeTime Director & CFO |
| Mr. Falin Majmudar | Additional Whole Time Director |
| Mr. Sandra Martyres | Independent Director |
| Mr. Sanker Parameswaran | Independent Director |
| Mr. Gira Sardesai | Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| Sun Pharmaceutical Industries | ₹4,10,130.32 | ₹1,709.35  ₹1,770.00(-3.43%) | ₹1,376.750 - ₹1,960.200 |
| Divi's Laboratories | ₹1,45,552.44 | ₹5,482.85 ₹5,763.00(-4.86%) | ₹3,613.550 - ₹6,448.750 |
| Cipla | ₹1,14,298.01 | ₹1,415.25 ₹1,495.70(-5.38%) | ₹1,317.600 - ₹1,702.000 |
| Torrent Pharmaceuticals | ₹1,11,230.09 | ₹3,286.50  ₹3,247.70(1.19%) | ₹2,508.650 - ₹3,589.950 |
| Mankind Pharma | ₹1,01,131.25 | ₹2,451.20 ₹2,427.70(0.97%) | ₹1,910.100 - ₹3,050.000 |
FAQs on Novartis India
What is the share price of Novartis India?
The share price of Novartis India on 04 Apr, 2025 is ₹ 802.10.
What is 52W high and 52W low share price of Novartis India?
The highest and lowest 52W share prices of Novartis India are ₹ 1248.000 and ₹ 744.950
What is the market cap of Novartis India?
The market capitalization of Novartis India as of 04 Apr, 2025 is ₹ 1,980.45 Crores
What is the P/E ratio of Novartis India?
The current P/E ratio of Novartis India as of 04 Apr, 2025 is 44.73
What is the PB ratio of Novartis India?
The PB ratio of Novartis India as of 04 Apr, 2025 is 2.66
Top Gainers
₹18.07
₹15.14 (0.19%)
₹66.60
₹57.80 (0.15%)
₹88.74
₹73.95 (0.20%)
₹197.50
₹167.35 (0.18%)
Top Losers
₹307.35
₹368.55 (-0.17%)
₹108.20
₹127.00 (-0.15%)
₹0.54
₹1.03 (-0.48%)
₹2,705.55
₹3,206.90 (-0.16%)
Market Indices
Sensex
₹75,364.69
₹76,295.36 (-0.01%)